The treatment of melasma by silymarin cream

BMC Family Practice

Tagreed Altaei¹ 

[1]Department of Pharmacology and Toxicology, College of Pharmacy, Hawler Medical University, Erbil City, Kurdistan, Iraq

关键词: Sunlight;    Melasma;    Silymarin;   

Others  :  855157
DOI  :  10.1186/1471-5945-12-18

 received in 2012-03-08, accepted in 2012-09-28,  发布年份 2012

【 摘 要 】

Background

Melasma is an acquired increased pigmentation of the skin characterized by symmetrical and confluent grey-brown patches usually on the areas of the face exposed to the sun. Silymarin strongly prevents photocarcinogenesis, and significantly prevented melanin production. The objectives of this study were the assessment of safety and efficacy of topical Silymain (SM) cream in a double-blind placebo controlled study for treatment of melasma patients.

Methods

Experimentally on 24 Albino rabbits were randomly divided into 4 equal groups. [A] No treatment, [B] received placebo, [C] treated with SM cream (0.1), & [D] treated by SM (0.2), were applied topically before UV sun light exposure for 30 days, assessed clinically & tissue pathology. Clinically on 96 adults diagnosed with melasma randomized to three equal groups to receive one of the tested drugs applied twice daily for 4 weeks, evaluated by the response; lesion size, melasma area and severity index score, Physician global assessment, and subjective assessment.

Results

The Clinical and histopathology observations were reduced significantly in SM groups. Clinically; all patients showed significant excellent pigment improvement & lesion size reduction with SM treatments from the 1^st week. All patients were fully satisfied 100%. No side effects were observed.

Conclusions

Silymarin showed tremendous improvement of melasma in a dose-dependent manner, and was effective in prevention of skin damage caused by U.V. sunlight. It is a safe new candidate effective treatment for melasma.

Trial registration

Australian New Zealand Clinical Trials Registry - ACTRN12612000602820

【 授权许可】

   
2012 Altaei; licensee BioMed Central Ltd.

【 图 表 】

Figure 2.

【 参考文献 】

• [1]Rendon M, Berneburg M, et al.: Treatment of melasma. J Am Acad Dermato 2006, 154(5 Suppl):S272-S281.
• [2]Wolff K, Johnson RA, et al.: Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology. Toronto: McGraw-Hill; 2005.
• [3]James WD, Berger TG, et al.: Andrews’ Diseases of the Skin Clinical Dermatology. Tenth edition. Toronto: Saunders Elsevier; 2006.
• [4]Hern R, Andez-Barrera B, Torres-Alvarez , et al.: Solar elastosis and presence of mast cells as key features in the pathogenesis of melasma. Clin Exp Dermatol 2008, 33(3):305-308.
• [5]Morazzoni P, Bombardelli E: Silybum marianum (Carduus marianus). Fitoterapia 1995, 64:3-42.
• [6]Vladimir K, Daniela W: Silybin and silymarin – new effects and applications. Biomed Papers 2005, 149(1):29-41.
• [7]Choo S-J, Ryoo , et al.: Silymarin inhibits melanin synthesis in melanocyte cells. J Pharm Pharmacol 2009, 61:663-667.
• [8]Hahn VG, Lehmann HD, et al.: Pharmacology and toxicology of silymarin, the antihepatotoxic agent of Silybum marianum (L.) Gaertn. Arzneimittelforschung 1968, 18:698-704.
• [9]Mereish KA, Bunner DL, et al.: Protection against microcystin-LR-induced hepatotoxicity by Silymarin: biochemistry, histopathology, and lethality. Pharm Res 1991, 8:273-277.
• [10]Wagner VH, Diesel P, et al.: Chemistry and analysis of silymarin from Silybum marianum Gaertn. Arzneimittelforschung 1974, 24:466-471.
• [11]Winfield AJ, Richards RME: Routes of administration and dosage forms. 3rd edition. Churchill Livingstone: 213; 2004:213-214. [Pharmaceutical practice]
• [12]Katiyar SK, Korman NJ, et al.: Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 1997, 89:556-566.
• [13]Katiyar SK: Treatment of silymarin, a plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin. Int J Oncol 2002, 21:1213-1222.
• [14]Kastan MB, Zhan Q, et al.: A mammalian cell cycle checkpoint pathway. Cell 1992, 71:587-597.
• [15]Shindo Y, Witt E, Han D, et al.: Enzymic and non-enzymic antioxidants in epidermis and dermis of human skin. J Invest Dermatol 1994, 102(1):122-124.
• [16]Fuchs J, Huflejt ME, et al.: Impairment of enzymic and nonenzymic antioxidants in skin by UVB irradiation. J Invest Dermatol 1989, 93(6):769-773.
• [17]Applegate LA, Lautier D, et al.: Endogenous glutathione levels modulate the frequency of both spontaneous and long wavelength ultraviolet induced mutation in human cells. Carcinogenesis 1992, 13:1557-1560.
• [18]Valenzuela A, Guerra R, et al.: Antioxidant properties of the flavonoids silybin and (+)-cyanidanol-3: comparison with butylated hydroxyanisole and butylated hydroxytoluene. Planta Med 1986, 5:438-440.
• [19]Rana P, Singh , Rajesh agarwal : Flavonoid Antioxidant Silymarin and Skin Cancer. Antioxid Redox Signal 2002, 4(4):655-663.